198 related articles for article (PubMed ID: 30122227)
21. Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents.
Dung do TM; Dung PT; Oanh DT; Hai PT; Huong le TT; Loi VD; Hahn H; Han BW; Kim J; Han SB; Nam NH
Med Chem; 2015; 11(8):725-35. PubMed ID: 26133355
[TBL] [Abstract][Full Text] [Related]
22. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
[TBL] [Abstract][Full Text] [Related]
23. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
[TBL] [Abstract][Full Text] [Related]
24. Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
Shao M; He L; Zheng L; Huang L; Zhou Y; Wang T; Chen Y; Shen M; Wang F; Yang Z; Chen L
Bioorg Med Chem Lett; 2017 Sep; 27(17):4051-4055. PubMed ID: 28765013
[TBL] [Abstract][Full Text] [Related]
25. Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.
Musso L; Cincinelli R; Zuco V; Zunino F; Nurisso A; Cuendet M; Giannini G; Vesci L; Pisano C; Dallavalle S
Bioorg Med Chem Lett; 2015 Oct; 25(20):4457-60. PubMed ID: 26376355
[TBL] [Abstract][Full Text] [Related]
26. 4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
Mehndiratta S; Wang RS; Huang HL; Su CJ; Hsu CM; Wu YW; Pan SL; Liou JP
Eur J Med Chem; 2017 Jul; 134():13-23. PubMed ID: 28395150
[TBL] [Abstract][Full Text] [Related]
27. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
[TBL] [Abstract][Full Text] [Related]
28. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors.
Mohamed MFA; Youssif BGM; Shaykoon MSA; Abdelrahman MH; Elsadek BEM; Aboraia AS; Abuo-Rahma GEA
Bioorg Chem; 2019 Oct; 91():103127. PubMed ID: 31374527
[TBL] [Abstract][Full Text] [Related]
29. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities.
Yang F; Peng S; Li Y; Su L; Peng Y; Wu J; Chen H; Liu M; Yi Z; Chen Y
Org Biomol Chem; 2016 Feb; 14(5):1727-35. PubMed ID: 26732459
[TBL] [Abstract][Full Text] [Related]
30. A novel series of l-2-benzyloxycarbonylamino-8-(2-pyridyl)-disulfidyloctanoic acid derivatives as histone deacetylase inhibitors: design, synthesis and molecular modeling study.
Huang D; Li X; Wei Y; Xiu Z
Eur J Med Chem; 2012 Jun; 52():111-22. PubMed ID: 22465091
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors.
Tian Y; Xie Z; Liao C
Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129
[TBL] [Abstract][Full Text] [Related]
32. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
Liu R; Wang J; Tang W; Fang H
Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
Xie R; Li Y; Tang P; Yuan Q
Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
[TBL] [Abstract][Full Text] [Related]
35. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
36. Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
Milelli A; Marchetti C; Turrini E; Catanzaro E; Mazzone R; Tomaselli D; Fimognari C; Tumiatti V; Minarini A
Bioorg Med Chem Lett; 2018 Apr; 28(6):1001-1004. PubMed ID: 29496367
[TBL] [Abstract][Full Text] [Related]
37. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
[TBL] [Abstract][Full Text] [Related]
38. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
Liao V; Liu T; Codd R
Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
[TBL] [Abstract][Full Text] [Related]
39. Quinolone-based HDAC inhibitors.
Balasubramanian G; Kilambi N; Rathinasamy S; Rajendran P; Narayanan S; Rajagopal S
J Enzyme Inhib Med Chem; 2014 Aug; 29(4):555-62. PubMed ID: 25019596
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]